The Pistoia Alliance Selects Eagle Genomics and Cycle Computing to Bolster Pharmaceutical R&D Practices

The Pistoia Alliance Selects Eagle Genomics and Cycle Computing to Bolster Pharmaceutical R&D Practices

New York - February 8, 2012 - Eagle Genomics and Cycle Computing today announced that they have jointly won a competitive bid by the Pistoia Alliance to support the development of a proof-of-concept (PoC) system to meet the future needs of pharmaceutical R&D IT. A four-month project, the Eagle Genomics & Cycle Computing proof-of-concept system is one of three accepted proposals out of a field of eleven total RFP submissions. A commercial release of the Sequencing Analysis Platform is expected by mid-2012.
The Pistoia Alliance, a global, not-for-profit, pre-competitive alliance of life science companies, vendors, publishers, and academic groups, with a vision for the future of managing and sharing pre-competitive pharmaceutical genomics R&D data, has created detailed requirements under the banner of Sequence Services Phase 2. The system, with a number of add-ons for analyzing this data through the use of standard bioinformatics tools and custom workflows, must ensure that each customer using it is completely confident that their data will remain private and confidential.
Building on Cycle Computing's extensive experience in securing and scaling large-data applications in the cloud, combined with Eagle Genomic's enviable track record in delivering bioinformatics applications and workflows to 8 out of 10 top global pharmaceutical companies, the joint Eagle/Cycle project is on track to be a robust, scalable, and highly adaptable solution that meets the vast majority of current Pistoia member needs, plus many of their future ones.
David Flanders, CEO of Eagle Genomics, said "The Pistoia Alliance's vision in recognizing the significance of disruptive technologies and associated new business models presents a superb showcase for the talents of Cycle Computing and Eagle Genomics to provide open innovation solutions to customers in the pharmaceutical sector - and beyond"
"Cycle is committed to supporting the standards that help spark innovation, unify silos and streamline data digestion," said Jason Stowe, CEO of Cycle Computing. "We look forward to collaborating with the alliance members and with the talent of Eagle Genomics in bioinformatics and Cycle Computing in Cloud HPC workflow management, meet the challenges facing both researchers today and into the next generation."
The proof-of-concept system for the Sequencing Analysis Platform will be delivered and demonstrated at the annual Pistoia Alliance Conference, to be held in March 2012 in Boston, MA. The award carries 25% of an overall $200K allocated by Pistoia.

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.